andriou
![]()
Posts:2
My wife shall contribute, for one year, in clinical trial with Taxotere - Ramucirumab or Placebo, as second-line therapy for NSCLC Stage IV. After 7 injections of the combination of both drugs, the Taxotere stopped and continues until today with only Ramucirumab or Placebo . About five months after starting therapy, metastases in the adrenal gland had stopped appearing on CT scans. The bulk remained stable. In the last CT scan, the bulk remains stable. But the adrenal glands appeared something described as "low density mass". I want to ask: Does this mean evolution and expulsion from the trial?
Forums
Reply # - December 4, 2012, 09:36 AM
Reply To: low density mass
Welcome Andriou, I'm so sorry your wife and you are going through all this.
All trials have their own sets of rules so it is impossible to say what this one will do in light of the findings. A low density mass where there was once a known cancer is suspicious though it doesn't always mean a change in treatment if it is felt the treatment is otherwise keeping cancer stable.
Please let us know how else we can help and keep us posted.
Janine
forum moderator
Reply # - December 4, 2012, 06:46 PM
Reply To: low density mass
Janine is quite right. There are specific criteria for what is defined as progression, and it may be left to the interpretation of the radiologist (the doctor who interprets imaging studies) or the treating oncologist whether the findings represent cancer progression or not.
Good luck.
-Dr. West